This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Penumbra Rallies 35.9% in a Year: What's Driving the Stock?
by Zacks Equity Research
PEN has shown notable strength over the past year, driven by the performance of its core U.S. thrombectomy business. Solid international prospects instill optimism.
Should Tandem Diabetes Stock Stay in Your Portfolio Now?
by Zacks Equity Research
Investors remain optimistic about TNDM, courtesy of its strong t:slim X2 performance and breakthrough innovations.
What Makes Phibro Animal Health (PAHC) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Phibro Animal Health (PAHC) have what it takes to be a top stock pick for momentum investors? Let's find out.
AST Business Growth & Strategic Acquisitions Support STERIS Stock
by Zacks Equity Research
STE frequently engages in strategic acquisitions and joint ventures to optimize its portfolio of businesses.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Medtronic Q4 Earnings and Revenues Top, Stock Down in Pre-market
by Zacks Equity Research
MDT delivers strong fourth-quarter fiscal 2025 results, with significant improvements in both gross and operating margins.
What's Driving Quest Diagnostics Stock's 25.6% Rally in a Year?
by Zacks Equity Research
DGX has shown notable strength in the past year, driven by robust core performance and contributions from acquisitions.
Should You Continue to Hold Charles River Stock in Your Portfolio?
by Zacks Equity Research
CRL stays on investors' radars due to the strength of partnerships and segmental prospects.
Illumina Stock to Gain From the Launch of New DRAGEN v4.4 Software
by Zacks Equity Research
ILMN's latest software features easy-to-use oncology apps, enhanced multiomics pipelines and AWS F2 support, enabling faster turnaround times.
Veracyte Stock Surges 30.9% in a Year: What's Driving the Rally?
by Zacks Equity Research
Strength in VCYT's Afirma and Decipher tests continues to draw investors' attention.
Should You Continue to Hold Medtronic Stock in Your Portfolio Now?
by Zacks Equity Research
Investors stay optimistic about MDT due to its strength in the Cardiovascular portfolio.
Should Edwards Lifesciences Stock Remain in Your Portfolio Now?
by Zacks Equity Research
EW stock is on investors' radars due to the promising structural heart opportunities and impressive TMTT portfolio.
STE Q4 Earnings Beat, Margins Expand, Stock Up in Aftermarket
by Zacks Equity Research
STERIS' fourth-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues.
Is it Worth Retaining Boston Scientific Stock in Your Portfolio Now?
by Zacks Equity Research
Investors continue to be optimistic about BSX, courtesy of its international expansion efforts and strategic acquisitions.
Why Phibro Animal Health (PAHC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
International Markets and Phibro (PAHC): A Deep Dive for Investors
by Zacks Equity Research
Examine the evolution of Phibro's (PAHC) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Should You Continue to Retain DGX Stock in Your Portfolio?
by Zacks Equity Research
Quest Diagnostics continues to stay on investors' radars due to its robust Advanced Diagnostics offerings and strength in acquisitions.
3 Reasons Growth Investors Will Love Phibro (PAHC)
by Zacks Equity Research
Phibro (PAHC) is well positioned to outperform the market, as it exhibits above-average growth in financials.
PAHC or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PAHC vs. BSX: Which Stock Is the Better Value Option?
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Phibro Q3 Earnings Top Estimates, Stock Up, 2025 EPS Outlook Raised
by Zacks Equity Research
PAHC's third-quarter fiscal 2025 results reflect the strength of the Animal Health segment.
Compared to Estimates, Phibro (PAHC) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Phibro (PAHC) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Phibro Animal Health (PAHC) Q3 Earnings Beat Estimates
by Zacks Equity Research
Phibro (PAHC) delivered earnings and revenue surprises of 21.15% and 0.78%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Phibro Animal Health (PAHC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Phibro (PAHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.